相关实验视频

Updated: Jan 16, 2026

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

抗炎药物用于COPD的管理 - Quo Vadis?

Agamemnon Bakakos¹, Zoi Sotiropoulou¹, Nektarios Anagnostopoulos¹

¹1st University Department of Respiratory Medicine, National and Kapodistrian University of Athens, Athens, Greece.

Respiratory medicine

|October 5, 2025

概括

新型抗炎疗法,包括固酶4抑制剂和针对2型炎症的生物药物,在治疗慢性阻塞性肺病 (COPD) 方面表现有前途. 基于炎症表型的个性化方法对于改善患者的治疗结果至关重要.

科学领域:

肺部医学肺部医学
炎症研究炎症研究
药理学药理学是指药理学的学科.

背景情况:

慢性阻塞性肺病 (COPD) 是一个主要的全球健康负担,其特点是由于慢性炎症导致的持续呼吸症状和渐进的空气流量限制.
目前的COPD治疗方法,包括支气管扩展剂和吸入性皮质类固醇 (ICS),不能阻止疾病的进展或防止恶化和肺功能下降.
迫切需要新的疗法来改变疾病的进展,而不仅仅是缓解症状.

研究的目的:

审查COPD抗炎药物的最新进展.
讨论针对COPD发病过程中的特定炎症途径的新型治疗策略.
突出基于COPD炎症表型的个性化药物的潜力.

主要方法:

对COPD新型抗炎药物最新研究的综述.
讨论固酶4 (PDE4) 抑制剂,双 PDE3/4 抑制剂 (例如,恩西芬林) 和生物疗法 (例如,针对 IL-5,IL-4/13 的单克隆抗体).
探索其他研究策略,如JAK抑制剂,化学因子受体对抗剂和向炎症细胞产物的药物.

主要成果:

吸入PDE4抑制剂和双PDE3/4抑制剂显示出抗炎和支气管扩展作用.
生物疗法,如Dupilumab (抗IL-4/13 mAb),已在减少异性慢性肺炎的恶化方面表现出有效性.
几种新型药物正在调查中,尽管有些人面临临临床试验失败.

结论:

随着COPD治疗的不断发展,需要针对个体炎症表型量身定制的个性化方法.
对新型抗炎药物的持续研究有可能显著改善COPD患者的治疗结果,并重塑治疗模式.
像恩西芬林和生物药物这样的创新疗法代表了转向COPD疾病修饰治疗的转变.

关键词:

抗炎药物是一种抗炎药物.慢性慢性肺炎是一种慢性慢性肺炎,COPD是一种慢性肺炎.慢性肺炎疾病的管理慢性慢性病治疗方法慢性慢性病治疗方法慢性慢性肺炎的试验COPD试验单克隆抗体是一种单克隆抗体.

更多相关视频

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia

Published on: May 30, 2025

相关概念视频

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Chronic Obstructive Pulmonary Disease-V: Management

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...